Record fucoidan production
Marinova is pleased to close 2025 having achieved record annual fucoidan production. The company's total production volume has more than doubled over the past three years.
“Global demand for Marinova’s high purity, certified organic fucoidan extracts has continued to increase throughout 2025,” said the company’s Production Manager, Mr Preben Soerensen. “Formulators and brand owners alike are increasingly searching for natural, efficacious ingredients supported by a transparent and sustainable supply chain. Fucoidan really does tick all the boxes.”
The increase in production aligns with the current growth being experienced in the global nutraceuticals market. Towards Healthcare recently reported the global market to be calculated at USD 636 billion in 2025 and expected to reach approximately USD 1234 billion by 2034, growing at a CAGR of 7.64%. The report predicts North America to experience the fastest growth in the market during this period, with lucrative expansion in the functional beverage market and significant growth in nutraceuticals targeting men’s health.
The same report highlights the ‘escalating consumer demand for preventative health solutions, rising disposable incomes and growing concern about lifestyle-related diseases’ as key drivers of market growth.
“We’re excited about the expanding opportunities in the global nutraceutical market and are well placed to meet the rising demand for fucoidan.” finished Mr Soerensen. “Marinova's recent expansion of its state-of-the-art fucoidan extraction facility provides timely assurance to its customers that global supply of high purity fucoidan is efficient, consistent and reliable.”